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1. Introduction 
The need to balance potency and physicochemical properties 
during medicinal chemistry optimisation is well established.1,2,3  
Undesirable values of simple physicochemical descriptors such as 
lipophilicity (logP, logD7.4) and size (molecular weight, heavy 
atom count) are associated with poor absorption, distribution, 
metabolism, elimination and toxicity (ADMET) properties such as 
low solubility, high metabolic clearance and increased activity at 
toxicological targets such as the human ether-à-go-go-related gene 
(hERG) channel.4  Nevertheless, medicinal chemists often 
continue to contend with large lipophilic compounds during 
optimisation because these typically bind well to protein targets 
and are therefore more likely to be found as a result of hit finding 
activities.  This is not necessarily a catastrophic situation provided 
medicinal chemists are aware of the fact and can conceive of 
strategies to address the shortcomings of their leads and evolve 
them towards more desirable regions of physicochemical space. 
Crude approaches to physicochemical optimisation involve the 
application of cut-off values for molecular weight and logP/D 
values such as Rule-of-5 criteria (MWt <500, logP <5).5  Because 
potency often increases with lipophilicity and molecular weight, 
the concept of normalising a biological potency value by 
descriptors of size, such as heavy atom count (HA) in the case of 
ligand efficiency (LE, Equation 1), or lipophilicity (lipophilic 
ligand efficiency, LLE or LipE, Equation 2) have been 
introduced.6  This initial concept has been expanded in an attempt 
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to combine multiple parameters such as size and lipophilicity 
(ligand efficiency dependent lipophilicity, LELP, equation 3).7 
LE = – 2.303 (RT/HA) × logKd = (1.37/HA) × pIC50 (1) 
LLE = pIC50 – logD7.4    (2) 
LELP = clogP / LE    (3) 
These concepts have attracted some criticism, chiefly due to 
their lack of thermodynamic basis and their underlying 
assumptions about the baseline relationships between their 
components, for example that potency should increase linearly 
with heavy atom count in the case of LE and that the relationship 
between potency and logD is linear with a slope of unity for 
LLE.8,9  These are valid considerations and make the combined 
assumptions that go into LELP hard to justify.  The question about 
the validity of the metrics continues to attract debate.10 
2. Selection of metrics 
One important consideration is that composite metrics have been 
employed for two different purposes.  Firstly, they have been used 
to facilitate comparison between different chemical series, for 
example to compare screening hits from different chemical series 
which differ from each other in their size or lipophilicity in order 
to determine which is most attractive.  Secondly, they have been 
applied to the assessment of how a small structural change within 
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a chemical series affects potency relative to its concomitant change 
in size or lipophilicity.  Qualitatively, these are both reasonable 
and helpful questions to ask.  We also contend that quantitative 
metrics such as LE and LLE are useful in informing these 
decisions and their application is valid provided one is aware of 
their assumptions and limitations. 
The focus of the majority of the reseach we describe here relates 
to lead optimisation and so we are concerned primarily with the 
assessment of structural changes within a series.  In that regard, we 
have found that LLE is the most helpful optimisation parameter 
since, in our experience, compound optimisation has primarily 
been concerned with the reduction in lipophilicity of compounds 
which were sufficiently potent, in order to improve their ADMET 
properties.  In that regard, we have generally not been examining 
changes that significantly altered the size of the compounds and 
hence LE has been uninformative.  Moreover, we were inherently 
attracted to the use of LLE as a metric because of the firm belief 
that muti-parameter optimisation can be greatly simplified by 
focussing on the design of potent compounds with low 
lipophilicity due to the propensity of the majority of ADMET 
proerties to be compromised when lipophilicity is high.4  
Secondly, it is reasonable to assume that for a small molecule 
binding to a hydrophobic protein pocket, potency will show a 
positive, linear relationship with lipophilicity in the absence of any 
differences in polar interactions between compounds.  This 
assumes that all compounds are within a suitable applicability 
domain, i.e. where the potency assay being used gives values that 
correlate with free energy and where lipophilicity can be measured 
accurately and is within an established range.  It is critical to 
establish as far as is reasonably practical that this is the case for 
the compounds in question.  Finally, the central assumption of the 
LLE parameter is that potency and lipophilicity not only correlate 
but do so with a slope of unity.  We believe this to be a reasonable 
assumption but would emphasise that LLE values should not be 
interpreted in isolation and should be considered in the context of 
the absolute potency and lipophilicity changes for a given 
transformation within a series and an analysis of the overall trend 
in the data, considering compounds where lipophilicity is likely to 
change in the absence of other binding events. 
Because the majority of ADMET properties correlate negatively 
with lipophilicity, the compounds with the optimal overall profile 
within a series would be expected to be those that were the most 
potent with the lowest lipophilicity i.e. highest LLE.  The one, and 
often only, execption to this trend is permeability, which generally 
decreases as lipophilicity decreases.  Hence, a critical component 
of the strategy of lipophilic optimisation is to establish the 
lipophilicity limit, for the series in question, at which permeability 
becomes too low.  The position of this limit is dependent on a 
number of factors including size and hydrogen bonding,11 hence 
our primary strategies for compound optimisation have been based 
on the idea of achieving the highest possible potency with 
lipophilicity values as low as the permeability limit allows. 
These concepts are easy to state and many articles have 
highlighted the value of property based optimisation and 
lipophilicity control.2,12,13  There has been relatively little 
discussion, however, on how these principles might be 
implemented in practice within projects14 with the majority of 
examples restricted to individual reported studies in which the 
focus of the discussion is the specific outcome of the optimisation 
and not the implementation of the approach.  Here we discuss our 
implementation of LLE based optimisation across a range of 
projects, many of which led to clinical candidates.  Importantly we 
highlight structural changes that led to improved LLE and were 
critical steps in project progression.  We believe that many of these 
experiences are generically applicable and will be of use in future 
optimisations. 
3. Measurement 
One factor, which we consider of critical importance for LLE 
based analysis is to use measured lipophilicity values and not rely 
on calculated values.  It is well established (but perhaps not widely 
appreciated) that calculated logP figures often vary significantly 
(with an average error of more than one log unit on average) from 
the true values.14  This variation is sufficient to render LLE’s 
derived from calculated values meaningless.  The requirement to 
measure logD7.4 values clearly requires extra experimental work, 
and the extra resource required may not be available to all 
researchers, but we would recommend that if possible, it is worth 
the investment for high resolution interpretation of structure 
activity relationships (SAR).  The use of chromatographic 
methods for determining lipophilicity values15 may reduce the 
resource requirement to obtain measured values. 
We encountered a prominent example of this phenomenon in 
our optimisation of G-protein coupled receptor 119 (GPR119) 
agonists for which three oxadiazole isomers were shown to have 
very different logD7.4 values, which were not predicted correctly 
(Figure 1).  In this case, using calculated (clogP) values would 
have led to the conclusion that compound 1 had the highest LLE, 
whereas the logD7.4 values show that 2 has the highest.  
Consequently, we can conclude that 1 is gaining its superior 
potency through increased lipophilicity and that 2 and 3 should 
offer a better balance of potency and physicochemical properties.  
The lower logD7.4 of 3 overall results in the most improved 
solubility and hERG potency. 
The above example deals with predominantly neutral 
compounds (no significant ionisation at pH 7.4) and so the logD7.4 
values are not significantly different to their logP values.  The 
difference between logD7.4 and clogP is due solely to inaccuracies 
in the clogP calculation.  Ionisation may be significant for some 
chemical series and this needs to be considered in the application 
of LLE.  Use of logD7.4 to derive LLE makes the assumption that 
binding of the ionised form to the target protein is negligible, 
which may be reasonable but needs to be considered if comparing 
compounds with differing pKa values that are close to 7.4 (±1).  
This introduces a second problem with using calculated values 
because simple pKa calculations can also carry significant errors. 
Figure 1 – a) Oxadiazole based GPR119 agonists and b) 
relationship between logD7.4 and potency across all compounds 
tested within this series, highlighting 1, 2 and 3. 
4. Correlations 
As stated in the introduction, a central assumption of the LLE 
metric, and a critical one to address if considering compounds 
across a range of lipophilicity values, is that the correlation 
between the selected measures of potency and lipophilicity is 
linear with a slope of unity, e.g. a unit increase in logD7.4 leads to 
a unit increase in pIC50, in the absence of any additional 
interactions.  We believe this is a reasonable assumption for a drug 
binding to a lipophilic pocket, after all, logD is intended to 
quantify the energy associated with a compound transferring from 
an aqueous to a lipophilic environment, but it should always be 
remembered that the chosen organic phase in the logD experiment 
(usually 1-octanol) is only a crude surrogate of a protein pocket.  
It is necessary to analyse the SAR to build confidence that the 
assumption holds for the target in question.  This is difficult, if not 
impossible, to do with absolute certainty because the majority of 
structural changes, such as additions of substituents to lead 
molecules, would be expected to change many other parameters to 
a varying degree in addition to lipophilicity and it is not possible 
to vary lipophilicity independently of other molecular properties – 
a significant problem with QSAR analyses in general.  A recent 
analysis of >2000 pairwise changes demonstrated that addition of 
a single methyl group, perhaps the simplest structural change that 
can be made and one that would lead to an increase in logP of ~0.5 
on average, could result in a potency change of ±2 log units with 
an average change of zero.16  This shows the extent to which 
potency can be modulated, presumably by changes in lipophilicity, 
electronic effects, conformational restriction and steric clashes by 
very small structural changes. 
Examination of overall trends in data where large numbers of 
compounds have been tested and examination of the “leading 
edge” of the correlation, where negative impacts of structural 
changes are minimised can be very informative in this regard.  For 
example, our series of GPR119 agonists show a logD potency 
correlation with a leading edge which is close to LLE=5 and has a 
slope which approximates to unity (Figure 1b).  Similarly, for a 
series of G-protein coupled receptor 40 (GPR40) antagonists, we 
observed a linear relationship between pEC50 and logD7.4 which 
showed a slope of 1.1 across 2 units of logD7.4 (Figure 2).
16  This 
is instructive, because we believe that the compounds bind to a 
protein pocket that is very hydrophobic in nature (and possesses a 
very hydrophobic endogenous ligand) and analysis of the SAR 
across the series was not suggestive of any of the compounds 
making additional polar interactions.  In this case, the inability to 
break this trend meant that we were unable to optimise the series 
towards a drug candidate but it is also informative of what an 
underlying potency:lipophilicity relationship is. 
Figure 2 – Potency : LogD7.4 relationships in a series of GPR40 
antagonists 
5. Improving ADMET properties 
The primary rationale for optimising LLE is that this is 
anticipated to lead to improved overall profiles of compounds and 
favour those with the best balance of potency and ADMET 
properties.  The application of LLE vastly simplifies the 
optimisation problem – it is very difficult to optimise compounds 
against potency and all of the individual ADMET parameters that 
need to be considered simultaneously (solubility, metabolic 
stability, hERG potency etc.) because analysis of poly-
dimensional SAR is difficult intellectually and subject to 
multiplication of experimental errors.  The multiparameter 
optimisation problem can be simplified if one can assume that 
identification of potent and polar compounds will result in the 
majority of ADMET properties falling into place.  Moreover, it 
also makes molecular design more rational and predictable 
because structural changes that manipulate lipophilicity are easy 
to conceive of and in prioritising synthesis targets, one might only 
need to speculate on which lipophilicity lowering changes might 
be most likely to maintain or increase potency. 
As an illustrative example, we have recently been able to 
optimise a series of bromodomain-containing protein 4 (BRD4) 
inhibitors, for which the lead molecules, such as 4, were highly 
lipophilic and suffered from poor solubility and metabolic 
stability, resulting in a lack of oral exposure (Figure 3).16  The 
change that addressed these problems was discovered by variation 
of the triazolopyrimidine substituent, which occupies a lipophilic 
region of BRD4 and is responsible for recognition of the methyl 
group of the acetylated lysine substrate.  Changing the initial 
trifluoromethyl substituent of 4 (logD7.4 >4) showed that LLE 
could be manipulated in this region although the majority of 
changes resulted in reduced potency relative to 4 despite increased 
LLE.  The highest LLE compound in this series was methoxy 
derivative 9, which had reduced lipophilicity and increased 
potency relative to 4.  This shows that large changes in LLE are 
possible (>3 log units in this case) with relatively small changes to 
structure.  It is also noteworthy that the logD7.4 values of these 
compounds do not change as their π-values would predict (CF3 
increases logD by >2.3 units, Δπ = 1.2 and OMe by 0.4, Δπ = 
0.0).  This is presumably due to the electronic interaction between 
the substituent and the nitrogen atoms of the heterocycle and 
highlights the need to obtain measured values.  As a result of its 
high LLE, 9 had the best balance of properties, including high 
solubility, low microsomal turnover and desirable 
pharmacokinetic properties.  This compound became our clinical 
candidate on the BRD4 project, designated AZD5153. 
In our 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1) 
project, we identified lead compound 11, which was moderately 
lipophilic but required improvement in potency and also suffered 
from metabolic instability resulting in no oral exposure (Figure 
4).17  Pharmacokinetic data suggested that metabolic instability 
was the primary reason for the lack of oral exposure although the 
compounds also suffered from sub-optimal solubility.  
Accordingly, our optimisation objectives were to increase LLE by 
both increasing potency and reducing lipophilicity.  It was 
discovered that introducing an additional substituent in the 6-
position of the pyridine that contained a carboxylic acid substituent 
addressed both of these objectives resulting in a 2.7 unit 
improvement in LLE and a 7 nM inhibitor, compound 12.  The 
reduction in lipophilicity resulted in improved solubility and 
metabolic stability giving 68% bioavailability in the rat.  This 
compound ultimately was selected as the development candidate 
AZD4017. 
Within this series, we also identified a back-up candidate that 
was structurally differentiated and was less prone to the formation  
 
Figure 3 – Optimisation of a series of triazolopyridazine based 
BRD4 inhibitors 
 
of acyl glucuronides - a potential risk associated with 12.18  The 
cyclopropyl pyrrolidine replacement for the piperidine increased 
steric congestion - to the acid and reduced the degree of 
glucuronidation of the carboxylate.  LLE could be balanced by 
increasing the lipophilicity of the 3-carboxamide substituent 
(cyclohexyl changed to adamantyl) and reducing the lipophilicity 
of the pyridine 2-substituent (propylthio- replaced with 
methylthio-) resulting in 13, which had a similar potency and 
lipophilicity to 12 (although further improved solubility) and was 
selected as the back-up candidate AZD6925. 
The most significant improvement in LLE arose from the 
incorporation of the carboxylate substituent.  It is interesting in this 
case that this leads to improved potency as well as reduced 
lipophilicity, with an X-ray crystal structure of 12 showing the acid 
positioned in close proximity to the backbone NH of Leu217 and 
the carboxylate of Asp259. Permeability remained acceptable for 
12 (MDCK Papp 290 nm.s
-1) but other members of the series with 
logD<2 showed reduced flux and reduced bioavailability in rat. 
Figure 4 - Optimisation of acidic 11-βHSD1 inhibitors 
Both of these examples show the improvement in solubility and 
metabolism resulting from reduced lipophilicity, which were 
achieved using structural changes that are well established to 
reduce logD7.4.  Improvements in solubility and metabolic stability 
with lowered lipophilicity within series are common trends.  
Aqueous solubility is a composite parameter derived from the 
activity coefficient (which is inversely correlated with 
lipophilicity) and lattice energy (for crystalline compounds).19  
Metabolic stability is generally inversely correlated with 
lipophilicity because the majority of metabolising enzymes such 
as CYP450’s have evolved to recognise lipophilic substrates for 
detoxification and elimination, hence more lipophilic compounds 
bind to CYP450 enzymes with greater affinity in general. 
Similar considerations apply to other ADMET parameters.4  
We suggest that reduction in lipophilicity should be the primary 
strategy to address ADMET issues.  Secondary strategies, such as 
disrupting crystal packing in the case of solubility or blocking 
groups for metabolism should only be considered once 
lipophilicity is controlled and in an appropriate range. 
6. Polar substituents and heterocycles 
Whilst we are usually able to rationally manipulate structures 
in a way that reduces lipophilicity, most commonly adding polar 
substituents or introducing heteroatoms, anecdotally, we believe 
that some strategies are superior to others in the sense that they are 
more likely lead to retained potency (improved LLE) or are less 
likely to compromise permeability as lipophilicity is reduced. 
In our optimisation of activators of glucokinase (GK), we 
identified lipophilic lead compound 14, which was potent but 
suffered from compromised ADMET properties, most notably 
hERG potency (Figure 5).19,20  As expected, these issues could be 
addressed by reducing lipophilicity and in this case, this was 
achieved in a potency neutral manner by replacing the thiazole 
with a pyrazole and the side chain methoxy substituent with a 
hydroxyl, resulting in 15, which had significantly reduced hERG 
potency and became a clinical candidate AZD1092.  The reduction 
in lipophilicity of this series led to diminished permeability as is 
illustrated by compromised Caco-2 Papp for 15. Further 
characterisation of the compound revealed this reduced 
permeability resulted in variable fraction absorbed across species 
(Fabs 50% in rat although higher in dog) presenting a risk that 
human Fabs may be low or variable. 
To address this, we embarked upon a follow up campaign 
focused on improving permeability whilst maintaining the other 
desirable properties of 15.21  The primary strategy to achieve this 
goal was to reduce the hydrogen bonding potential of the 
compounds by replacing the hydroxyl group H-bond donor.  One 
successful way to do this was to return to methyl ether derivatives 
but this would clearly increase lipophilicity.  Therefore, 
concomitantly, we explored additional strategies to lower logD in 
other parts of the structure and found that this could be achieved 
without detriment to potency by replacing the pendant phenyl ring 
with 6-membered heterocycles.  In the event, pyrazine was 
particularly beneficial in improving LLE (increased by 0.6 units 
relative to phenyl).  These changes were instrumental in 
identifying the clinical candidate from this series 16 (AZD1656), 
which had a superior technical profile to 15, including 
significantly improved permeability and 100% bioavailability 
across species and which progressed to Phase II clinical testing. 
Key learning from this program was that introduction of 
heterocycles was a superior strategy to introducing polar, H-
bonding substituents as this enabled reduction in lipophilicity 
without as much detriment to permeability, ultimately leading to a 
compound with a much better overall profile.  The SAR for the 
introduction of heterocycles is also noteworthy, pyrazine was by 
far the best replacement for phenyl and the corresponding 
pyridines were inferior, with the 2-pyridyl isomer 17 losing 
potency relative to phenyl 19 and the 3-isomer 18 not showing a 
reduction in logD7.4 relative to 19 (the hydrogen bond acceptor 
potential of the nitrogen is significantly diminished when it is 
ortho- to a strong electron withdrawing group).  Hence, the 
improvement offered by pyrazine could not be predicted from the 
two corresponding pyridine derivatives.  In our experience, 
diazines are often show superior LLE than the corresponding 
pyridines and should be explored systematically in late stage 
optimisation regardless of the data on the pyridine analogues; the 
other four possible diazines were inferior to pyrazine in this case. 
Figure 5 - LLE, hERG potency and permeability of a series of 
GK activators 
In our search for inhibitors of doubly-mutated (DM) epidermal 
growth factor receptor tyrosine kinase (EGFR), we identified a 
series of indole-substituted pyrimidines that were potent and 
offered some selectivity in a cellular setting over the wild-type 
(WT) kinase, exemplified by compound 20 (Figure 6).22  Despite 
promising activity data, 20 was too lipophilic and had no oral 
exposure in rats.  Following some of the considerations outlined 
above, we set out to reduce lipophilicity and found that this could 
be achieved without too much detriment to potency by replacing 
the indole with a pyrazolopyridine (introduction of heteroatoms) 
and by appending a basic dimethylamino group to the acrylamide 
(introduction of ionisable groups) resulting in 21, which had oral 
exposure in the rat and served as the first in vivo probe compound 
for the project. 
We then set out to reduce the predicted human dose of the 
compounds to acceptable levels by examining further 
improvements in LLE and we discovered that potency gains could 
be made by shifting the base from the acrylamide to the para-
position of the phenyl ring (22), increasing potency and reducing 
logD7.4 simultaneously (3 unit improvement in LLE).
23  This not 
only resulted in a superior compound, but also allowed greater 
scope to explore structural variations in the rest of the molecule.  
Most critically, this allowed a reinvestigation of indole 
substituents on the pyrimidine, which were more potent against 
single mutant (SM) EGFR.  A compound with equipotency against 
the DM and SM forms of the kinase offered a more desirable 
clinical profile but previously, indole substituents had been ruled 
out because they led to compounds that were too lipophilic. This 
now enabled their further investigation with a wider variety of 
additional substitution.  The most productive variations were the 
combinations of substitutions of the indole nitrogen (leading to a 
further increase in logD7.4) with variations of the pyrimidine 5-
substituent (e.g. removal of the chloro), which allowed 
lipophilicity to be balanced and the selectivity against IGFR to be 
improved.  This exercise led to the identification of 23, among 
many other compounds, which was less potent and more lipophilic 
than 22 but was unique in that it showed significantly diminished 
insulin-like growth factor receptor (IGFR) and hERG potency – 
two critical selectivity targets.  Whilst 23 therefore does not have 
the highest LLE in the series, the discovery of its unique selectivity 
would not have been possible without the LLE optimisation that 
preceded its discovery.  The compound 23 was nominated as a 
clinical candidate (AZD9291) and is now marketed as 
TAGRISSO™ (osimertinib). 
Figure 6 – Mutant EGFR inhibitors 
7. Conformational restriction 
A long running programme investigating diacyl glycerol acetyl 
transferase 1 (DGAT1) inhibitors revealed a sub-series of triaryl 
derivatives, which originated from the unsubstituted biphenyl 
compound 24 (Figure 7).15  This compound fell short of the 
required target potency but had very low lipohilicity and was 
considered a promising lead.  Because 24 contains a carboxylate, 
which was shown to be required for potency we considered it 
essential for our optimisation programme that the logD7.4 was not 
increased significantly.  In our experience, the critical optimisation 
parameter for acidic compounds is to minimise clearance of the 
compounds, usually to a level that they show no detectable 
turnover in hepatocyte incubations, because higher clearance 
values result in human dose predictions that are too high and carry 
significant uncertainty due to their low volume of distribution.  
The best strategy to achieve this is to make the compounds as polar 
as their permeability limit allows.  Optimisation of carboxylic 
acids introduces an additional risk, specifically arising from the 
potential to form acyl glucuronides, which may be reactive 
metabolites.24  On the other hand, we have recently shown that 
carboxylic acids carry a lower overall risk of failing in 
development for toxicological reasons but are more likely to fail 
due to poor pharmacokinetics.25  Together, these factors strongly 
suggest that maximising LLE in acids is highly desirable as a 
means to minimise the propensity for metabolism and reduce the 
overall dose. 
In our case, the permeability limit occurs at very low logD7.4 
because the compounds are relatively small26 and so we considered 
the best strategy for optimisation to be to increase potency whilst 
maintaining logD7.4 in a similar range to 24 but without 
significantly increasing molecular size.  One option to achieve 
these ends is to explore conformational restriction to freeze out the 
bioactive conformation of the molecule and reduce the entropic 
penalty of binding.  Also of consideration in this case is the array 
of three contiguous aryl rings and we were aware that flat, 
polyaromatic compounds are often associated with additional 
problems such as low solubility that may be worse than predicted 
by their lipophilicity alone.15  Taking these considerations 
together, one attractive avenue of SAR exploration was to 
introduce small substituents that would favour a non-coplanar 
conformations.  Frequently, destabilising planar conformations of 
biaryl systems with lipophilic substituents does not increase 
lipophilicity as much as the substituent contributions might 
predict. 
Accordingly, we investigated the introduction of a chloro-
substituent at all four possible positions on the aromatic ring.  
Substitution ortho- to the acetic acid or pyrazine substituents 
resulted in reduced potency relative to 24.  Substitution in the 
central phenyl ring ortho- to the other phenyl moiety (25) resulted 
in an increase in potency with only modest increase in logD7.4 
(ΔLLE +0.5), indicating that an orthogonal orientation of the two 
phenyl rings represents the likely bioactive conformation.  The 
permeability of 25, measured by MDCK Papp, was moderate, 
indicating that logD7.4 of 0.6 was still close to the permeability 
limit.  Consistent with this theory, changing the chloro for a cyano 
substituent led to lower logD7.4 and poor permeability (logD7.4 = -
0.4 and MDCK Papp = 12 nm.s-1).  Incorporating a chloro- 
substituent on the distal phenyl ring meta- to the acetic acid (26) 
led to a greater improvement in potency (ΔLLE +1.8 relative to 
24).  Since the effect on conformation arising from substitution in 
this position is the same as that for 25, we interpret this to mean 
that the chloro- of 26 is making an additional contact with the 
protein target leading to the greater increase in affinity.  
Simultaneous substitution at both of these promising positions 
served to reinforce the improvement and ultimately, the 
combination of chloro- and fluoro- substituents, combined with a 
methyl substituent α- to the carboxylate led to the optimised 
compound 27.  This is equipotent with 26 but has a slightly 
increased logD, which although detrimental to LLE, results in high 
permeability.  This compound was selected as the development 
candidate AZD2353. 
Figure 7 – Optimisation of triaryl DGAT1 inhibitors 
An extreme form of conformational restriction that has been 
popularised recently is macrocyclisation.27,28  Interest in 
macrocycles has derived chiefly from the desire to access regions 
of high molecular weight for less tractable drug targets such as 
protein-protein interactions.  We have found macrocyclisation to 
be a very effective strategy to increase potency without changes in 
lipophilicity.  In our 2-hydroxy-dATP diphosphohydrolase 
(MTH1) project, we identified lead compound 28, which required 
an increase in potency whilst maintaining its low lipophilicity 
(Figure 8).  Analysis of the X-ray crystal structure of 28 in 
complex with MTH1 revealed that the methoxyethyl side chain to 
be in close proximity to the phenyl ring in the bound conformation.  
This is a high energy conformation in which repulsive interactions 
between these groups occur and so 28 would be expected to 
encounter substantial entropic penalties to binding.  Covalently 
linking these substituents together, initially with an alkyl chain to 
form a macrocycle (29), locked the substituents in the active 
conformation.  This resulted in a substantial increase in potency 
with only a small increase in lipophilicity (ΔLLE +2.3).  
Lipophilicity could be reduced by incorporating an ether in the 
linking chain (30), which had a similar lipophilicity to 28 but was 
three orders of magnitude more potent, presumably due to the 
ligand being effectively pre-organised into the bioactive 
conformation. 
Figure 8 – Macrocyclisation as a strategy for lipophilicity 
neutral increases in potency in a) MTH1 inhibitors and b) BCL6 
inhibitors 
A second example of the effect of macrocyclisation comes from 
our B-cell lymphoma 6 (BCL6) inhibitor program where 
conformational restriction afforded significant boosts in potency 
for no increase in lipophilicity and consequently, increased LLE. 
Here, comparing acyclic precursors 31 and 33 with their 
corresponding macrocyclised derivatives 32 and 34, shows that 
both pairs exhibit comparable increases in LLE (+2.3 and +2.2 
respectively) despite having different lipophilicity values (2.1 and 
-0.3).29 
8. Recent Literature 
The examples above are drawn from the authors’ experiences 
at AstraZeneca, however, the use of LLE as an optimsation tool 
has become more widely accepted by medicinal chemists in recent 
years.30,31  Below, we present some noteworthy examples of this 
approach from the recent literature (Figure 9). Researchers at 
Merck describe the use of LLE in the optimsation of a series of 
Janus kinase 1 inhibitors from tool 35 to advanced lead 36.32  The 
incorporation of a polar atom (cyclohexyl switched to 
tetrahydropyran) proved a key breakthrough improving both 
hERG and PK parameters. A second example from Merck 
describes the use of LLE to drive improvements  in drug like 
properties in a series of undecaprenyl-phosphate N-
acetylglucosaminyl 1-phosphate transfersae inhibitors.33  Here an 
impressive 5 unit drop in lipophilicity was achieved from 
startpoint 37 (clogP 7.1) to more polar 38 (clogP 1.9) through the 
inclusion of polar functionality (aryl to heteroaryl and methyl to 
hydroxyl) whilst potency was maintained (LLE +4.5). Genentech 
have reported the optimsation of a pyrazole series of dual leucine 
zipper kinase inhibitors from 39 to in vivo tool 40 with control of 
LLE and polar surface area (PSA) being key drivers to improve 
physical properties and CNS penetration.34 
We also highlight examples of the use of LLE where the lead 
compounds have undergone significant changes in molecular size 
(Figure 10).  An impressive example of a fragment based 
optimsation is described by Pfizer where a weak hit from a screen 
against interleukin-1 receptor associated kinase 4 (41) was 
optimised to the clinical candidate 42 (PF-06650833) with an 
overall LLE of +4.9..35  Conversely, LLE was also used in the 
deconstruction of a lipophilic mRNA decapping scavenger 
enzyme inhibitor hit 43 (clogP 5.3) to a smaller, more polar in vivo 
tool 44 (LLE of +2.6) with improved physicochemical 
properties.36  Lastly, an example of structurally enabled 
hybridisation of two fragment hits 45 LLE 1.3) and 46 LLE 1.1) 
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optimisation led to compound 47 LLE 6.9) which demonstrated 
in vivo efficacy and improved ADMET properties.37 
Figure 9 – Literature examples of LLE optimisation 
 
Figure 10 – LLE optimisation with changes in size 
9. Conclusions 
The examples we describe are not intended to be 
comprehensive, such an extensive review is beyond the scope of 
this article.  However, we highlight influential aspects of our own 
work, along with prominent work from the literature, that illustrate 
considerations that we believe are generically applicable.  In a 
general sense, the strategies we describe can be used to derive a 
set of heuristic guidelines, which we believe should be considered 
as part of any LLE based optimisation strategy. 
- Address ADMET properties primarily by lipophilicity 
control. 
- Use measured logD for analysis. 
- Establish a lower limit of lipophilicity for the series based 
on permeability data.  Target the highest possible potency 
with the lowest lipophilicity permitted by the permeability 
limit. 
- Reduce lipophilicity without making significant increases 
in H-bonding or size to maintain / increase permeability 
window and target much lower regions of logD. 
- Introduce heteroatoms in preference to the addition of 
polar substituents, these changes are more likely to be 
tolerated and are less detrimental to permeability. 
- Avoid large increase in molecular weight.  Improve 
potency by optimisation of existing substituents and 
controlling conformations. 
- Exploit ionisable groups where they increase potency. 
- X-ray structures may be useful in identifying polar 
interactions to target but experimental exploration of the 
SAR is needed. 
Whilst we have focused our interpretation on LLE, the 
combination of lipophilicity with sub-structural descriptors such 
as aromatic ring count15 or proportions of sp3 hybridised atoms,38 
have also been suggested as indicators of compound “quality”.  We 
believe that in general, the introduction of increased three-
dimensional character to molecules during optimisation, which are 
the underlying principles of these additional metrics, is likely to be 
beneficial, and in line with the guidelines that we propose.  We 
would contend, however, that their combination into single 
molecular descriptors compromises interpretability.  Such metrics 
have generally been applied to analyzing large, structurally diverse 
datasets.  Within the context of an optimisation programme, more 
complex analysis of SAR will be carried out, and application of 
combined descriptors is unnecessary. 
Many of the examples we have discussed here fall within the 
chemical space defined by Rule of Five criteria.  Optimisation of 
compounds that do not comply with all of these criteria may be 
necessary for some challenging targets and is increasingly gaining 
traction.  In this area, it is likely that high values of LLE are harder 
to achieve.  However, we would consider that analysis of SAR 
using LLE is likely to remain useful in such projects, provided it 
is applied with consideration of the context of the target in 
question. 
Whilst we anticipate that healthy debate about the physical 
validity of LLE will continue, we have repeatedly found it to be a 
useful guide to simplify the problem of multiparameter 
optimisation and focus efforts towards identifying potent 
compounds with low lipophilicity.  The application of these 
principles has been repeatedly shown to provide an effective and 
efficient means of identifying clinical candidates.  We hope that 
by highlighting and classifying the key structural changes that 
have been beneficial in these projects, further improvements in 
lead optimisation strategies will be facilitated and ultimately, more 
successful medicines will be discovered with greater efficiency. 
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